TEM

Business Context and Reporting Period

Tempus AI, Inc. (TEM) is a healthcare technology company focused on applying artificial intelligence and machine learning to improve patient care through genomic testing and data analytics. This Form 10-Q covers the quarterly period ended September 30, 2024. The company completed its Initial Public Offering (IPO) on June 17, 2024, raising net proceeds of approximately $382 million. As of the reporting date, the company is classified as an emerging growth company and a non-accelerated filer.

Key Financial Metrics

Note: Debt figures include the Convertible Promissory Note ($174.5 million) and Long-term debt, net ($264.5 million).

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 33% year-over-year in Q3 2024, driven by a 20% increase in Genomics revenue (due to higher oncology NGS test volume) and a 64% increase in Data and Services revenue (driven by demand for Insights products).
• Expense Surge: Selling, General, and Administrative (SG&A) expenses increased 42% in Q3 and 204% for the nine months ended September 30, 2024. This was primarily due to $389.6 million in stock-based compensation expense recognized in the nine-month period following the satisfaction of liquidity event vesting conditions upon the IPO.
• Net Loss Expansion: The net loss for the nine months ended September 30, 2024, widened significantly to $692.8 million compared to $163.6 million in the prior year period, largely attributable to the one-time stock-based compensation charge and increased operating expenses.
• Joint Venture Investment: The company invested $95.2 million in a new joint venture with SoftBank (SB Tempus) in July 2024, recorded as an investment in joint venture on the balance sheet.

Guidance, Outlook, and Risks

• Acquisition of Ambry Genetics: On November 4, 2024, Tempus entered into an agreement to acquire Ambry Genetics Corporation for approximately $375 million in cash and 4.8 million shares of Class A common stock. The deal is expected to close in Q1 2025, subject to regulatory approvals.
• Financing for Acquisition: Tempus secured a commitment from Ares Capital Corporation for a $100 million revolving credit facility and $200 million in additional term loans to fund the Ambry acquisition.
• Debt Covenants: The company must maintain minimum consolidated revenues of $459.1 million for the year ended December 31, 2024, and $594.1 million for 2025 to remain in compliance with its Term Loan Facility covenants.
• Legal Proceedings: The company is facing a patent infringement lawsuit filed by Guardant Health regarding liquid biopsy technology. Additionally, the company is responding to a Civil Investigative Demand from the U.S. Attorney's Office regarding compliance with the False Claims Act and Medicare billing rules.
• Stock-Based Compensation: Management expects to continue recording stock-based compensation expenses as RSUs vest, though the magnitude of the IPO-related charge is a one-time event.

Investor Verification Checklist

• Revenue Run Rate vs. Debt Covenants: Verify if the company is on track to meet the $459.1 million revenue requirement for the full year 2024 to avoid default on its Term Loan Facility.
• Stock-Based Compensation Impact: Confirm the extent to which the $509 million stock-based compensation charge in the first nine months of 2024 distorts the view of ongoing operational profitability.
• Reimbursement Trends: Monitor updates on Medicare and commercial payer reimbursement rates for NGS tests, as changes here directly impact gross margins and revenue recognition.
• Acquisition Financing: Track the execution of the definitive debt documentation with Ares Capital Corporation required to close the Ambry Genetics acquisition.
• Legal Exposure: Assess the potential financial impact of the Guardant Health patent litigation and the ongoing government investigation into billing practices.